8 active not recruiting, 4 completed, 3 recruiting, 2 terminated. 13 Phase 2, 4 Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.
Follow Stage III Bladder Cancer AJCC v8: new trials by email Literature Review of Stage III Bladder Cancer AJCC v8 trials Research Report on Stage III Bladder Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent - Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | University of Washington | 12 | 2026-08-20 | 2026-08-25 |
| Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial Biospecimen Collection, Computed Tomography, Cystectomy - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma | Phase 4 | Recruiting | Mayo Clinic | 75 | 2025-01-08 | 2026-10-01 |
| An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers Assessment of Distress, Consultation Visit, Nutritional Assessment - Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma | Not applicable | Active not recruiting | Roswell Park Cancer Institute | 12 | 2024-01-12 | 2026-11-05 |
| Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Atezolizumab, Biospecimen Collection, Computed Tomography - Bladder Carcinoma, Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2023-10-12 | 2025-10-21 | |
| Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma | Phase 2 | Recruiting | Emory University | 25 | 2023-09-26 | 2026-07-29 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-11-12 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-11-17 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial Biopsy of Bladder, Biospecimen Collection, Cisplatin - Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2021-03-17 | 2026-11-17 |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 60 | 2020-11-03 | 2026-11-18 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2019-11-18 | 2026-11-18 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-11-18 |
| Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy Pembrolizumab - Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2018-01-11 | 2024-06-25 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-11-18 |
Urinary Bladder Neoplasms (18) · Ureteral Neoplasms (9) · Urethral Neoplasms (7) · Carcinoma, Transitional Cell (4) · Carcinoma, Renal Cell (3) · Lung Neoplasms (2) · Urogenital Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Penile Neoplasms (1) · Prostatic Neoplasms (1)
Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Male Urogenital Diseases (18) · Neoplasms by Site (18) · Urinary Bladder Diseases (18) · Urogenital Diseases (18) · Urologic Diseases (18) · Urologic Neoplasms (18) · Neoplasms (17) · Urogenital Neoplasms (16) · Ureteral Diseases (9) · Neoplasms by Histologic Type (8) · Carcinoma (7) · Neoplasms, Glandular and Epithelial (7) · Urethral Diseases (7)
Magnetic Resonance Spectroscopy (10) · Specimen Handling (10) · pembrolizumab (5) · Biopsy (4) · Nivolumab (4) · atezolizumab (4) · Cystoscopy (3) · Disulfides (3) · Immunoglobulin G (3) · Radiation (3) · Radiotherapy (3) · avelumab (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · CTLA-4 Antigen (2) · Cisplatin (2)
National Cancer Institute (NCI) (8) · M.D. Anderson Cancer Center (4) · Mayo Clinic (2) · City of Hope Medical Center (1) · Emory University (1) · Roswell Park Cancer Institute (1) · University of Washington (1)
United States (17) · Canada (2)
Andrea B Apolo (2) · Anishka A D'Souza (1) · Di Maria Jiang (1) · Evan Y Yu (1) · Jacob J. Orme, MD, PhD (1) · Jacqueline Brown, MD (1) · Laleh Melstrom (1) · Maha H Hussain (1) · Monika Joshi (1) · Neema Navai (1) · Paras H. Shah, MD (1) · Parminder Singh (1) · Rodabe Amaria, MD (1) · Saby George, MD (1) · Sangeeta Goswami (1)
PMID 32915679, PMID 35031545, PMID 35537412, PMID 37328287, PMID 38954785, PMID 40580957
UM1CA186717 (2), ZIABC011078 (2), P30CA015704 (1), P30CA033572 (1), P30CA060553 (1), P30CA138292 (1), U01CA154967 (1), U10CA180820 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186712 (1), UM1CA186716 (1)